Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (72)

Latest Posts

About This Stock More About This Stock
E Market Briefing For Tuesday, Oct.27
Article By: Gene Inger
Tuesday, October 27, 2020 3:32 AM EDT
Jarring metrics combined to impact economic and market expectations, by a crowd that had been in-denial or hoping more progress would occur sooner. That sure applies to political wrangling about 'Stimulus', which continues to run-into roadblocks.
In this article: LVS, SAP, CRNT, REGN Also: JPM, LLY, T, SRNE, VODPF, QQQ, AAPL, AMZN, SPY, TMUS
Read
E Market Briefing For Thursday, Oct. 15
Article By: Gene Inger
Thursday, October 15, 2020 3:10 AM EDT
It is a more cautious time, based on pandemic, on politics, on expensive stock leadership, while the more-mundane stocks aren't particularly pricey at all. But of course that presumes we emerge from the bunker-lifestyle quickly enough.
In this article: SRNE, REGN, LPTH Also: AAPL, SPX, HTBX
Read
Trump's Endorsement A Double-Edged Sword For Regeneron
Article By: David Pinsen
Friday, October 9, 2020 5:15 AM EDT
President Trump's touting of Regeneron's COVID-19 treatment boosted the stock, but also added an element of political risk to it. We elaborate and show how cautious bulls can stay long while strictly limiting their risk.
In this article: REGN Also: LLY
Read
Regeneron Rallies After Seeking Emergency-Use Approval For Antibody Cocktail Hailed As "Cure" By Trump
Article By: Tyler Durden
Thursday, October 8, 2020 7:05 AM EDT
Shares of Regeneron are ripping higher Thursday in premarket trading, building on its gains from Wednesday evening, after the company submitted its COVID-19 antibody cocktail to the FDA for emergency-use approval.
In this article: LLY, REGN
Read
E Market Briefing For Monday, Oct. 5
Article By: Gene Inger
Sunday, October 4, 2020 8:01 PM EDT
Tremendous near-term uncertainty. with light at the end of the Covid tunnel if and when.
In this article: SRNE, REGN, VIX, NYA
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!

$REGN

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments